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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.08.002Choroidal metastasis from prostate adenocarcinoma is exceedingly rare. Furthermore, data addressing the
optimal therapeutic strategy is limited. A 62-year-old male patient with metastatic prostate cancer was
found to have a choroidal metastasis after complaining of decreased vision in his left eye. Following treat-
ment with external beam radiotherapy, complete response in the choroidal metastasis was demonstrated. A
literature search was undertaken to highlight the therapeutic options for this rare presentation. Choroidal
metastasis secondary to adenocarcinoma of the prostate is exceedingly rare, as only eight cases have been
reported so far. External beam radiotherapy is an effective therapeutic modality.INTRODUCTIONhe choroid accounts for around 90% of metas-
tasis to the uveal tract.1 Although breast and
lung cancers are the most common carcinomas
to metastasize to this site, it is extremely rare for pros-
tate carcinoma to present within this site of metasta-
sis. Herein, we present a case of prostatic carcinoma
with choroidal metastasis, and review the relevant lit-
erature in an attempt to highlight the available thera-
peutic strategies.CASE
A 62-year-old diabetic male was referred to us for fur-
ther management for his recently diagnosed prostate
cancer. He initially presented to his primary care phy-
sician with persistent lower urinary tract symptoms.
A urinary ultrasound showed an enlarged prostate
gland, and blood tests showed a high prostate speciﬁc
antigen (PSA) reading of 275 ng/ml. A trans-rectal
ultrasound guided prostate biopsy that was done be-
fore his presentation to us was reported as prostate
adenocarcinoma, with a Gleason score of 9 (5+4),
involving 40% of the specimen. The patient reported
bone pains persisting over a period of two months.Physical examination was remarkable for bone
tenderness over the lateral chest wall and upper back.
Blood tests showed a high PSA of 270 ng/ml, and
alkaline phosphatase of 339 IU/L; other laboratory
tests were within normal limits. Computed axial
tomography scan of his chest, abdomen, and pelvis
showed a small cortical cyst in the upper pole of the
left kidney, and an enlarged prostate gland indenting
the posterior wall of the urinary bladder with strand-
ing of pelvic fat. Bone scan demonstrated widespread
bone metastases. A review of his prostate biopsy spec-
imen conﬁrmed the diagnosis of prostate adenocarci-
noma, with a Gleason score of 8 (4+4), in 2 out of
3 cores, involving 70% of core tissue. Therapy with
Bicalutamide 50 mg orally once daily was initiated
and continued for two weeks, in addition to one injec-
tion of the long acting luteinizing hormone-releasing
hormone (LHRH) agonist Triptorelin, administered
as 11.25 mg intramuscular injection. One month la-
ter, he underwent bilateral subcapsular orchidectomy.
Three months following orchidectomy, the patient re-
ported resolution of his bone pains, and his PSA de-
clined to 7.5 ng/ml. Unfortunately, six months later,
his PSA rose again to a value of 54.4 ng/ml, and
his bone scan showed new bone lesions suggestive of
disease progression. Computed tomography (CT)arter 2015
Figure 2. B-scan ultrasound of the left eye revealing a dome shaped,
elevated choroidal lesion with moderate internal reflectivity
representing the metastatic lesion.
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scan of his chest, abdomen, and pelvis ruled out any
visceral progression. Therapy with Bicalutamide was
re-initiated. Shortly thereafter, he started to complain
of decrease in vision in the left eye and was referred
for the ophthalmologist for evaluation of possible dia-
betic retinopathy. Fundus examination of his left eye
showed ill-deﬁned yellow to white elevated choroidal
lesion nasal to the disc (Figure 1). Fluorescein angiog-
raphy of the left eye revealed early hypoﬂuorescence
and late phase showed hypoﬂuorescence from the sur-
face of his choroidal lesion. A B-scan ultrasound of his
left eye revealed a dome shaped, elevated choroidal le-
sion with moderate internal reﬂectivity (Figure 2).
These ﬁndings were consistent with choroidal metas-
tasis. Unfortunately, visual ﬁeld testing was not
performed.
We decided to proceed with palliative external
beam radiation therapy (EBRT) to the left orbit.
CT-simulation was performed with the patient in
the supine position using a thermoplastic head mask.
The patient received EBRT as 3000 cGy/10 fractions
over two weeks to the left orbit via a 3-D conformal
irradiation technique. A direct antero-posterior and
lateral ﬁeld were utilized. The planning target volume
was covered by 98.5% of the prescribed radiation dose
(Figure 3). The patient tolerated treatment fairly well
with no appreciable acute side effects. Following com-
pletion of radiotherapy, follow-up ophthalmic evalua-
tion demonstrated complete resolution of the
choroidal lesion with associated pigmentation. The
patient remained free of choroidal recurrence accord-
ing to the last assessment, 14 months following com-
pletion of radiotherapy.
The choroid is a rare site of involvement by meta-
static carcinomas. In a survey that included 8712 pa-
tients, only six patients (0.07%) were found to have
choroidal metastases.2 Most choroidal metastases are
secondary to breast or lung carcinomas, and exceed-Figure 1. Left eye funduscopic examination revealing an elevated
choroidal lesion nasal to the disc, representing a choroidal metastasis.
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Necropsy studies of patients dying of cancer at Wil-
mer Institute showed a 4.2% rate of ocular metastases
in patients dying of prostate cancer.3 Nevertheless,
most of these cases have asymptomatic choroidal
metastases.
The diagnosis of choroidal metastasis is usually
clinical and supported by radiologic evidence of met-
astatic cancer in other organs. In this setting, the
metastasis is identiﬁed as a solid, ﬂat, plaque-like,
mottled, yellow brown lesion that is commonly asso-
ciated with serous retinal detachment. Biopsy should
be considered in patients with less straightforward
presentation in order to exclude second primary
tumor.
Being aware of the variety of treatment options is
of paramount importance, as preservation of vision
would be the most important palliative aim for pa-
tients with incurable and metastatic disease.
EBRT is effective in treating and palliating pa-
tients with asymptomatic and symptomatic choroidal
metastases. Doses in the range of 3000 to 4000 cGy
delivered via conventional fractionation are well toler-
ated and result in visual/objective stabilization and/or
improvement in up to 85% of cases.4,5 According to
numerous reports, a unilateral radiation portal is
appropriate in patients presenting with unilateral cho-
roidal metastasis.6 However, it should be noted that
most patients included in these studies had a diagno-
sis of metastatic breast and lung cancer and only very
few presented with choroidal involvement secondary
to a prostate neoplasm.
There had been only eight reports in the literature
for patients with metastatic prostate cancer who
develop metastasis in the choroid (Table 1). These
patients commonly have other sites of metastatic
disease.35
Figure 3. Axial, sagittal and coronal CT-simulation images showing the beam orientations and the isodose lines of the delivered radiation plan.
36
case report CHOROIDAL METASTASIS SECONDARY TO PROSTATIC ADENOCARCINOMATo the best of our knowledge, there had been only
three reported cases of choroidal metastasis from
prostate cancer that were treated with EBRT, all
showing dramatic improvement in vision and almost
complete resolution of choroidal metastasis following
EBRT.7–9
Potential acute side-effects following ocular irradi-
ation include erythema, keratitis, corneal ulceration
and retinal edema.10,11 In like manner, possible
long-term sequelae include necrosis, cataract, dry
eye, retinopathy, blindness and second malig-
nancy.12,13 Damage to the optic nerve and chiasm
are extremely unlikely at the utilized radiation dose
(3000 cGy).14
Data from the reported cases suggest that hor-
monal therapy including anti-androgens and luteiniz-
ing hormone releasing hormone (LHRH) agonists are
also effective.15 Objective visual improvement had
consistently been reported within 4–8 weeks of start-
ing therapy.
Selection of the therapeutic modality for pa-
tients with choroidal metastases secondary to pros-
tate cancer depends on the hormone responsive
state of the disease, availability of EBRT, and cost.
In patients whose disease is still hormone sensitive,we recommend either EBRT or using an anti-
androgen with or without an LHRH agonist. On
the other hand, for patients whose disease had al-
ready progressed following hormonal therapy, we
recommend EBRT as the only known effective
therapeutic modality.CONCLUSION
The choroid is an exceedingly rare site of involvement
by metastasis from prostate carcinoma. Oncologists
and ophthalmologists have to be aware of this kind
of presentation as early initiation of therapy is impor-
tant to preserve vision. EBRT and hormonal options
are effective therapeutic options. Our patient showed
complete resolution of his choroidal lesion following
radiotherapy.CONSENT
Written informed consent was obtained from the
patient for publication of this case report and any
accompanying images. A copy of the written con-
sent is available for review by the Editor of this
journal.Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015
Table 1. Characteristics of eight reported cases of prostate cancer and choroidal metastases.
First Author/Journal Age Laterality Complaint Metastatic
sites
Treatment Outcome
First Author/Journal Age Laterality Complaint Metastatic
sites
Treatment Outcome
Dieckert JP. Br J Ophthalmol.
1982 Apr; 66(4):234–9
54 Left Decreased vision 4 months Lungs, bone Bilateral
orchidectomy + DES
Restoration of normal vision after 4 weeks, CR after
2 months
Kancherla S. Retina Today, Jan/
Feb 2011
68 Left Decreased vision 4 months Bone EBRT Almost complete resolution and improvement in vision
after 1 year
Barbn JJ. Arch Soc Esp Oftalmol.
2007 Nov;82(11):715–7
74 Left No specific visual symptoms.
Hemiparesis, cranial mass
Bone, brain Bicalutamide + LHRH
agonist
CR after 2 months. Vision remained the same.
Remession maintained at 14 months
Keizur JJ. Prostate. 1995
Dec;27(6):336–9
Not
clear
Bilateral Decreased vision Not clear Androgen deprivation CR
Frota AC. Can J Ophthalmol. 2007
Apr;42(2):305-6
72 Left Decreased vision No other
sites
Chemotherapy and
brachytherapy
Decrease choroidal dimensions and improved vision
Primavera V. J Fr Opthalmol. 2008
Nov;31(9):877–82
54 Bilateral Decreased vision in left eye of
1 month
Bone and
lungs
Bicalutamide and
Triptorelin injection
CR
Ermoian RP. Retinal Cases & Brief
Reports: Fall 2011;5(4):306–8
60 Rt Decreased vision in Rt eye Metastatic to
other sites
EBRT Dramatic improvement in vision. Maintained normal
vision 2.5 years after EBRT despite systemic PD
Obek C. Urology. 2001
Jul;58(1):106
49 Rt Decreased vision in Rt eye Not reported Total androgen
blockade and EBRT
CR choroidal metastasis. DWD 32 months after
diagnosis
DES: Diethylstilbestrol; EBRT: External beam radiotherapy; LHRH: Luteinizing hormone releasing hormone; CR: Complete response; PD: Progression of disease; DWD: Died with disease.
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